Regeneron Pharmaceuticals
-
Phase III studies with VEGF Trap-Eye in wet age-related macular degeneration show sustained improvement in visual acuity
Bayer HealthCare and Regeneron Pharmaceuticals announced that in an integrated analysis of two parallel Phase III studies (VIEW 1 and VIEW 2) in patients with the neovascular form of age-related macular degeneration (wet AMD), patients treated with VEGF Trap-Eye showed a sustained improvement in visual acuity at 96 weeks versus baseline.
Regeneron Pharmaceuticals | 25 January 2012
